Impact of Biweekly and Triweekly Dosing Regimens on Progression-Free Survival in First-Line FOLFIRI Treatment of Metastatic Colorectal Cancer: A Non-Inferiority Study (FIR-DIR)

When bowel cancer spreads to other parts of the body, it's called metastatic colorectal cancer. Doctors often use a powerful chemotherapy treatment called FOLFIRI to help control it. FOLFIRI is a mix of three different drugs: Irinotecan, Calcium Folinate, and Fluorouracil. These drugs work together to slow down or stop cancer cells from growing. Having chemotherapy can be tough, and the number of times you have it can affect how you feel and how much time you spend in hospital.

This study is looking at whether giving FOLFIRI treatment less often could still be just as good at keeping the cancer under control. Currently, it's often given frequently. The researchers want to compare two different schedules: one where patients get the treatment every two weeks, and another where they get it every three weeks. The main goal is to see if the every-three-weeks schedule is similar in effectiveness to the every-two-weeks schedule at stopping the cancer from growing or spreading further. This 'stopping the cancer from getting worse' is what doctors call 'progression-free survival'.

If the study finds that giving FOLFIRI less often is just as effective, it could mean that patients might need fewer hospital visits and potentially experience fewer side effects over time. This could really improve their quality of life while still getting effective cancer treatment. The researchers will also be carefully watching for how long people live overall, how long they can stay on the treatment, and any side effects or problems that might happen with either schedule. This is a Phase II study, which means it's an early stage but still an important step in finding the best ways to treat cancer.